Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    antineoplaston | Phase 3
Show Display Options
Rank Status Study
1 Withdrawn Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
Condition: Optic Nerve Glioma
Interventions: Drug: Temozolomide;   Drug: ANP Therapy

Indicates status has not been verified in more than two years